<DOC>
	<DOCNO>NCT02329496</DOCNO>
	<brief_summary>To confirm acute performance safety Lotus™ Valve Next Generation Delivery System transcatheter aortic valve replacement ( TAVR ) symptomatic patient severe calcific aortic stenosis consider high risk surgical valve replacement .</brief_summary>
	<brief_title>REPRISE Next Generation Delivery System</brief_title>
	<detailed_description>This clinical study prospective single-arm study design demonstrate acute performance safety LOTUS Edge Valve System use iSleeve Introducer Set current Lotus Introducer Set consistent result Lotus Valve System use REPRISE II study , deliver deploy symptomatic subject severe calcific aortic valve stenosis high risk surgical aortic valve replacement ( SAVR ) .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject ≥70 year age 2 . Subject document calcific native aortic valve stenosis initial aortic valve area ( AVA ) ≤1.0 cm2 ( AVA index ≤0.6 cm2/m2 ) either mean pressure gradient ≥40 mm Hg jet velocity ≥4 m/s , measure echocardiography . 3 . Subject document aortic annulus size ≥20 ≤27.5 mm base preprocedure diagnostic imaging 4 . Subject symptomatic aortic valve stenosis NYHA Functional Class ≥ II . 5 . Subject consider high risk surgical valve replacement base least one following : Society Thoracic Surgeons ( STS ) score ≥8 % , and/or Agreement heart team ( must include inperson evaluation experience cardiac surgeon ) subject high operative risk serious morbidity mortality surgical valve replacement . 6 . Heart team ( must include experienced cardiac surgeon ) assessment subject likely benefit valve replacement 7 . Subject ( legal representative ) understand study requirement treatment procedure , provide write informed consent . 8 . Subject , family member and/or legal representative agree ( ) subject capable return study hospital require schedule follow visit . 1 . Subject congenital unicuspid bicuspid aortic valve . 2 . Subject acute myocardial infarction within 30 day index procedure ( define Qwave MI nonQwave MI total CK elevation ≥ twice normal presence creatine kinasemyoglobin band ( CKMB ) elevation and/or troponin level elevation ) . 3 . Subject cerebrovascular accident transient ischemic attack within past 6 month , permanent neurologic defect prior study enrollment . 4 . Subject dialysis serum creatinine level &gt; 3.0 mg/dL 265 µml/L . 5 . Subject preexist prosthetic heart valve ( aortic mitral ) prosthetic ring position . 6 . Subject ≥3+ mitral regurgitation , ≥3+ aortic regurgitation ≥3+ tricuspid regurgitation ( i.e. , subject moderate mitral , aortic tricuspid regurgitation ) . 7 . Subject need emergency surgery reason . 8 . Subject history endocarditis within 12 month index procedure evidence active systemic infection sepsis . 9 . Subject echocardiographic evidence intracardiac mass , thrombus vegetation . 10 . Subject Hgb &lt; 9 g/dL , platelet count &lt; 50,000 cells/mm3 &gt; 700,000 cells/mm3 , white blood cell count &lt; 1,000 cells/mm3 . 11 . Subject receive chronic ( ≥72 hour ) anticoagulation therapy ( warfarin ) , tolerate concomitant therapy aspirin clopidogrel ( subject require chronic anticoagulation must additionally able treat either aspirin clopidogrel ) . * 12 . Subject active peptic ulcer disease gastrointestinal bleed within past 3 month , bleed diathesis coagulopathy refuse transfusion . 13 . Subject know hypersensitivity contrast agent adequately premedicated , know hypersensitivity aspirin , thienopyridines , heparin , nickel , titanium , polyurethane . 14 . Subject life expectancy le 12 month due noncardiac , comorbid condition base assessment investigator time enrollment . 15 . Subject hypertrophic obstructive cardiomyopathy . 16 . Subject therapeutic invasive cardiac procedure within 30 day prior index procedure ( except balloon aortic valvuloplasty pacemaker implantation allow ) . 17 . Subject untreated coronary artery disease , opinion treat physician , clinically significant require revascularization . 18 . Subject document left ventricular ejection fraction &lt; 30 % . 19 . Subject cardiogenic shock hemodynamic instability require inotropic support mechanical support device . 20 . Subject severe peripheral vascular disease ( include aneurysm define maximal luminal diameter &gt; 5 cm document presence thrombus , mark tortuosity , narrow abdominal aorta , severe unfold thoracic aorta thick [ &gt; 5 mm ] protrude ulcerated atheroma aortic arch ) symptomatic carotid vertebral disease . 21 . Femoral artery lumen &lt; 6.0 mm subject require 23 mm valve size &lt; 6.5 mm subject require 27 mm valve size , severe iliofemoral tortuosity calcification would prevent safe placement introducer sheath . 22 . Current problem substance abuse ( e.g. , alcohol , etc. ) . 23 . Subject participate another investigational drug device study reach primary endpoint . 24 . Subject untreated conduction system disorder ( e.g. , Type II second degree atrioventricular block ) opinion treat physician clinically significant require pacemaker implantation .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>